​

Atai Life Sciences N.V.

NasdaqGM:ATAI Stock Report

Market Cap: US$587.6m

Atai Life Sciences (ATAI) Stock Overview

A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. More details

ATAI fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 67.17% per year

Risk Analysis

Does not have meaningful revenue ($2M)

Shareholders have been diluted in the past year

Volatile share price over the past 3 months compared to the US market

Currently unprofitable and not forecast to become profitable over the next 3 years


ATAI Community Fair Values

Create Narrative

See what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.

Atai Life Sciences N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Atai Life Sciences
Historical stock prices
Current Share PriceUS$2.75
52 Week HighUS$2.99
52 Week LowUS$1.03
Beta1.45
1 Month Change14.11%
3 Month Change127.27%
1 Year Change116.54%
3 Year Change-34.83%
5 Year Changen/a
Change since IPO-85.86%

Recent News & Updates

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Jul 02

Despite Lacking Profits Atai Life Sciences (NASDAQ:ATAI) Seems To Be On Top Of Its Debt

May 16
Despite Lacking Profits Atai Life Sciences (NASDAQ:ATAI) Seems To Be On Top Of Its Debt

Recent updates

Atai: Critical Study Win Sets Up Double Approval Shot For Psychedelics In TRD

Jul 02

Despite Lacking Profits Atai Life Sciences (NASDAQ:ATAI) Seems To Be On Top Of Its Debt

May 16
Despite Lacking Profits Atai Life Sciences (NASDAQ:ATAI) Seems To Be On Top Of Its Debt

Atai Life Sciences: Pipeline And Regulatory Uncertainties Warrant Hold Rating

Apr 21

Atai: Following The Path That Spravato Laid And Moving Beyond It

Feb 27

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

Jan 29

Psychedelic Stock Deep Dive: Atai Life Sciences

Sep 03

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?

Jul 15
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?

ATAI: Enormous Potential Upside But No Clarity Yet

May 27

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?

Mar 02
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?

atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug

Oct 12

Atai Life Sciences: Decentralized Drug Discovery Platform

Oct 06

ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01

Aug 15

We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Aug 07
We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer

Jul 07

atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO

Jun 30

Atai Life Sciences N.V.: A First Take

Jun 02

Atai Life Sciences And The Future Of Psychedelics For Mental Health

May 27

We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Apr 22
We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Shareholder Returns

ATAIUS PharmaceuticalsUS Market
7D25.6%1.8%1.8%
1Y116.5%-10.1%13.7%

Return vs Industry: ATAI exceeded the US Pharmaceuticals industry which returned -10.1% over the past year.

Return vs Market: ATAI exceeded the US Market which returned 13.7% over the past year.

Price Volatility

Is ATAI's price volatile compared to industry and market?
ATAI volatility
ATAI Average Weekly Movement13.4%
Pharmaceuticals Industry Average Movement10.9%
Market Average Movement7.3%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.7%

Stable Share Price: ATAI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ATAI's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201854Srini Raoatai.com

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD.

Atai Life Sciences N.V. Fundamentals Summary

How do Atai Life Sciences's earnings and revenue compare to its market cap?
ATAI fundamental statistics
Market capUS$587.64m
Earnings (TTM)-US$148.99m
Revenue (TTM)US$1.86m
313.1x
P/S Ratio
-3.9x
P/E Ratio

Is ATAI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATAI income statement (TTM)
RevenueUS$1.86m
Cost of Revenue-US$392.00k
Gross ProfitUS$2.26m
Other ExpensesUS$151.24m
Earnings-US$148.99m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.70
Gross Margin121.04%
Net Profit Margin-7,997.16%
Debt/Equity Ratio17.1%

How did ATAI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/07 23:09
End of Day Share Price 2025/07/07 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atai Life Sciences N.V. is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David BoucheyAegis Capital Corporation
Harry GillisBerenberg
Sumant Satchidanand KulkarniCanaccord Genuity